Drugs / Young TIL

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT01585415 Apr 2012 → Jul 2016 melanoma, metastatic malignant neoplasm National Cancer Institute (NCI) Terminated No outcome recorded
Phase 26 trials
Phase 2 NCT02621021 Dec 2015 → Jun 2028 expected melanoma National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 2 NCT02133196 Oct 2014 → Oct 2027 expected adenocarcinoma, adenosquamous carcinoma, non-small cell lung carcinoma National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 2 NCT01993719 Dec 2013 → Oct 2021 metastatic melanoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT01585428 Apr 2012 → Apr 2016 anus cancer, cervical cancer, oropharyngeal carcinoma, penile cancer +1 National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT01319565 Mar 2011 → Sep 2024 metastatic melanoma, skin cancer National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT01174121 Aug 2010 → Dec 2028 expected breast carcinoma, colorectal cancer, malignant pancreatic neoplasm, neuroendocrine neoplasm +1 National Cancer Institute (NCI) Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Young TIL ClinicalTrials.gov intervention name — accepted as the source's own label NCT01585428
6

NCT01993719

NCT01585415

NCT02621021

NCT02133196

NCT01174121

NCT01319565

Modality Cell therapy “autologous TIL” NCT01174121
Route Intravenous “Cells will be infused intravenously (IV)” NCT01174121